Infusions & Injections

ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of rheumatoid arthritis (RA), giant cell arthritis (GCA), systemic sclerosis-associated interstitial lung disease (SSc-ILD), polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA), and cytokine release syndrome (CRS). This medication is available as an infusion or a subcutaneous injection.

AMVUTTRA® (vutrisiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This medication targets the transthyretin (TTR) gene to reduce the production of abnormal TTR protein, which can accumulate in tissues and cause damage in patients with hATTR. AMVUTTRA is administered as a subcutaneous injection once every three months, offering a long-acting treatment option for managing this progressive condition.

Apretude® (cabotegravir extended-release injectable suspension) is an FDA-approved pre-exposure prophylaxis (PrEP) medication used to reduce the risk of sexually acquired HIV-1 in eligible HIV-negative adults and adolescents weighing at least 35 kg (77 lbs). Administered as an intramuscular injection every two months following the initial doses, Apretude offers a long-acting alternative to daily oral PrEP medication.

AVSOLA® (infliximab-axxq) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis

BENLYSTA® (belimumab) is a B-lymphocyte stimulator (BLyS) inhibitor indicated for the treatment of systemic lupus erythematosus (SLE) in autoantibody-positive adult patients, and active lupus nephritis

BONIVA® (ibrandronate sodium) is an infusion therapy FDA-approved for the treatment and prevention of postmenopausal osteoporosis.

BRUIMVI® (brucemizumab) is a monoclonal antibody therapeutic indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This medication targets the CD20 protein on the surface of B-cells, a type of immune cell that plays a role in the autoimmune process underlying MS. By depleting these B-cells, BRUIMVI helps to reduce inflammation and prevent the progression of disability associated with MS. BRUIMVI is administered as an intravenous infusion, typically given every 6 months after an initial loading phase, offering a long-acting treatment option for managing this chronic neuroinflammatory disease.

CABENUVA® (cabotegravir and riplivirine) is an FDA-approved complete long-acting antiretroviral regimen administered intramuscularly monthly or every two months for the treatment of HIV-1 infection in virologically suppressed adults and adolescents.

CIMZIA® (certolizumab pegol) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis

COAGADEX® (Coagulation Factor X [Human]) is an FDA-approved plasma-derived Factor X replacement therapy administered by intravenous infusion for the routine prophylaxis and on-demand treatment of bleeding episodes in patients with hereditary Factor X deficiency.